About

Copious research efforts have been undertaken in MS research in the last three decades to unravel immune mechanisms in the periphery thought to be responsible for disease onset and effector mechanisms mediating CNS damage.  However, the underlying molecular causes of MS are still not understood and prognostic estimates can hardly be given to patients in the absence of valid surrogate markers.  Traditional therapeutic disease modifying regimens aim at immunomodulation or immunosuppression and were developed in the context of autoimmune research in conjunction with other diseases such as rheumatoid arthritis, Crohn’s disease and diabetes mellitus.  However, response to anti-inflammatory therapeutic interventions differs significantly between MS and other autoimmune disorders.  Moreover, in many MS patients, response to the current interventions has only limited impact on disease progression.  Finally, novel therapies in MS aimed at reducing the CNS-directed immune responses are associated with a severe risk for opportunistic CNS infection.

There is currently an urgent need to go back to basics and apply completely novel ideas and unconventional methods as well as brand new technologies to research in this area.  Now is the time to take up the challenge and, for the first time in Germany, promote interaction between strong research groups at three different sites that all have the ideal prerequisites for illuminating and expanding highly novel and innovative perspectives in MS research.  The goal of this consortium, which consists of scientists from centers in the Rhine-Main area, Münster and Munich, is to unravel the pathology of MS and develop as well as understand novel therapeutic concepts.  The ideal prerequisites for such progress are provided by effectively linking scientists from neighboring disciplines with classical neuroimmunologists, who possess a proven track record in MS research and patient care and arise from an important and internationally visible nucleus in this field.  One key aspect here is the strong bidirectional crosstalk between pure experimental research in animal models and clinical research in human systems and patients, which allows the best transfer of basic knowledge into clinical care – and vice versa.

News

Thu, 20/04/2017
International Symposium 2017: SFB Junior Researchers Present their Projects
Muenster. For the second time, the Cluster of Excellence “Cells in Motion” hosts an international symposium. In interdisciplinary sessions and talks, international top class scientists will present their current research questions and findings. The list of speakers comprises experts from chemistry, mathematics, physics, biology and medicine, going beyond the boundaries of specialised fields and reflecting […]...more
Thu, 20/04/2017
“Cardiac regeneration: from zebrafish to mammals”
Muenster. At the lecture series “Piomeers in Cell Dynamic and Imaging” international guests as well as scientists from the Cells-in-Motion Cluster of Excellence and the biomedical Collaborative Research Centres of the University of Münster present their most recent scientific advances in basic and translational research. In April, Felix Engel, Professor for Experimental Renal and Cardiovascular […]...more
Thu, 20/04/2017
Spotlight on Formyl Peptide Chemoattractant Receptors
Muenster. The CRC Breaking Barriers: Immune cells and pathogens at cell / matrix barriers cordially invites interested audience to attend its upcoming Jour-Fixe Meeting. SFB scientists Ursula Rescher and Volker Gerkewill talk about Formyl peptide chemoattractant receptors in leukocyte activation and trans-endothelial migration. When?: Monday, April 24, 1:00 PM Where?: Lecture Hall, Department of Dermatology, […]...more